EUVIMEDEUVIMED entdecken
Crossref

0306 Early survival benefit of SARS-CoV-2 mRNA vaccination during immune checkpoint inhibitor therapy in cutaneous melanoma & squamous cell carcinoma

D. Mendez, M.A. Hill, N. Guzman, J. Arbesman

Journal of Investigative Dermatology · 2026-08 · 146 (8) · S53

DOI: 10.1016/j.jid.2026.06.337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2026-08. Verfasst von D. Mendez und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Mendez, D., Hill, M., Guzman, N., & Arbesman, J. (2026). 0306 Early survival benefit of SARS-CoV-2 mRNA vaccination during immune checkpoint inhibitor therapy in cutaneous melanoma & squamous cell carcinoma. Journal of Investigative Dermatology, 146(8), S53. https://doi.org/10.1016/j.jid.2026.06.337

Vancouver

Mendez D, Hill M, Guzman N, Arbesman J. 0306 Early survival benefit of SARS-CoV-2 mRNA vaccination during immune checkpoint inhibitor therapy in cutaneous melanoma & squamous cell carcinoma. Journal of Investigative Dermatology. 2026;146(8):S53. doi:10.1016/j.jid.2026.06.337

BibTeX
@article{Mendez2026,
  author = {Mendez, D. and Hill, M.A. and Guzman, N. and Arbesman, J.},
  title = {0306 Early survival benefit of SARS-CoV-2 mRNA vaccination during immune checkpoint inhibitor therapy in cutaneous melanoma & squamous cell carcinoma},
  journal = {Journal of Investigative Dermatology},
  year = {2026},
  volume = {146},
  number = {8},
  pages = {S53},
  doi = {10.1016/j.jid.2026.06.337}
}
Kostenlos starten →